1. Home
  2. Community
  3. Promotions

  4. Cyagen HUGO-Ab™ & Biointron AbDrop™ High-Throughput Fully Human Antibody Discovery Platform

Cyagen HUGO-AbTM & Biointron AbDropTM
High-throughput Fully Humanized Antibody Discovery Platform
Discuss Your Project
Enhanced Accuracy & Diversity
Faster Results
Simplified & Streamlined
Cost-Effectiveness
Overview

Safer and More Efficient Fully Humanized
Antibody Discovery in as Fast as 3 Months

Fully human antibodies, entirely encoded by human genes, offer a significant advantage in antibody drug development. They trigger minimal immune response (immunogenicity) in patients, leading to improved safety and tolerance compared to traditional antibody therapies. This approach also focuses on identifying high-affinity and highly specific antibodies, ensuring they effectively target the desired molecules. Previously, researchers relied on humanized mice, genetically modified to produce human antibodies, for this purpose.

However, with the innovative combination of Biointron's AbDropTM and Cyagen's HUGO-AbTM mice enables more efficient fully human antibody discovery. Our High-throughput Fully Humanized Antibody Discovery Platform eliminates the need for complex modifications and simplifies the development process, reducing costs and accelerating the discovery of safer and more effective antibody drugs.

Revolutionizing Antibody Discovery: Cyagen & Biointron Partner on Next-Gen Platform

Cyagen and Biointron have joined forces to create a breakthrough platform for discovering fully human antibodies. This collaboration combines Cyagen's HUGO-AbTM fully humanized antibody mice - with Biointron's innovative AbDropTM technology - a microdroplet-based platform for single B cell antibody discovery.

This powerful alliance streamlines the process like never before:

Faster Results

Go from target to fully human antibody in just 3 months, eliminating the need for time-consuming humanization modifications.

Enhanced Accuracy & Diversity

Access a rich pool of diverse, high-quality antibody sequences for superior targeting potential.

Simplified & Streamlined

Benefit from straightforward intellectual property (IP) and patent licensing, ensuring a smooth development process

Cost-Effectiveness

Reduce development costs and timelines significantly, accelerating your path to market.

Our revolutionary platform paves the way for faster, more efficient, and cost-effective discovery of high-quality human antibodies,leading to better therapeutic options for patients.

Cyagen HUGO-AbTM Mice: The Key to Fully Human Antibodies

Cyagen's HUGO-AbTM mice represent a breakthrough in antibody discovery. These innovative mice are genetically engineered to produce fully human antibodies, eliminating the need for complex humanization steps. This translates to several key advantages:

Next-Generation Humanization: HUGO-AbTM mice are engineered using our proprietary TurboKnockout® ES technology, which replaces the VH and VL genes in situ to offer more stable phenotypic and functional outcomes in progeny than traditional transgenic methods.

Highlights

High Affinity & Low Immunogenicity

HUGO-AbTM mice generate antibodies that bind tightly to their targets (high affinity) while minimizing immune response in patients (low immunogenicity), leading to safer and more effective drugs.

Proven Performance

Recognized by leading pharmaceutical companies and academic institutions, HUGO-AbTM mice have delivered excellent results in the discovery of new antibody-based therapies.

Efficient Engine for Drug Development

By streamlining the antibody discovery process, HUGO-AbTM mice act as a powerful engine for the development of novel therapeutic drugs.
HUGO-AbTM Mouse Model: Scheme of Humanization Strategy of Heavy Chain and Light Chain
Why Choose HUGO-AbTM?

HUGO-Ab™ mice represent a cutting-edge platform for the development of antibody-based therapeutics. Cyagen offers a diverse portfolio of HUGO-Ab™ models, including HUGO-Mab™, HUGO-Light™, HUGO-Nano™ and HUGO-eKO™. Each model is tailored to meet specific research needs in antibody discovery, ensuring high efficacy and applicability across various therapeutic areas.

Biointron's AbDrop™ Platform: The Power of Microfluidics
Biointron's AbDropTM platform leverages microfluidic technology as the screening method to generate droplets encapsulating individual plasma cells.
Working Flowchart
Case 1: HUGO-AbTM Mice Exhibit a High-Titer Immune Response to the PDL1 Antigen
After antigen immunization, we measured the serum titers of different mice after 2nd, 3rd, and 4th immunizations. All serum titers reached a level above 1024K. We then selected the one with the highest titer - mice #427 -for fully human antibody screening.
Case 2: The AbDropTM Single B-Cell Antibody Discovery Platform Efficiently Screens PDL1-positive Cells
After enrichment with CD138 beads, all 2×10^6 cells/mL were loaded into the machine and cultured for 2 hours, resulting in 7,921 positive droplets.
Note: 419, 424, 425, 427, and 428 are the sequence numbers of HUGO-AbTM fully human antibody mice.
Case 3: The Fully Humanized Antibody Discovery Platform Generates a Diverse Array of Fully Human Antibody Sequences

The screened cells were subjected to single-cell sequencing, capturing 1,809 cells. Among these, 1,466 cells (81.62%) had V(D) sequence characteristics.

HUMAN
1,809 Estimated Number of Cells
68,210 Mean Reads per Cell
1,466Number of Cells With Productive V-J Spanning Pai

Case 4: The Fully Humanized Antibody Discovery Platform Obtains High-Quality Antibody Sequence Molecules

Anti-PDL1 candidate molecules were analyzed in vitro. SAI-427-1, SAI-427-3, SA1-427-5, SAI-427-8, SAI-427-11, and SAl-427-15 are candidate molecules derived from HUGO-AbTM mice; Atezolizumab was used as the reference antibody.
Advanced Antibody Development FAQs
Learn how our innovative technologies streamline antibody production.
Explore
Inquire About Our Platforms

Thank you for reaching out! We will respond within 2 business days. We appreciate your trust in us!

Cyagen values your privacy. We'd like to keep you informed about our latest offerings and insights. Your preferences: